ARCHIVES

NCI declined to pay for economic, quality of life analysis in Avastin, Erbitux study.

This article is from The Cancer Letter archive.

Vol. 31 No. 22 | June 3, 2005

Download PDF Visit The Full Archive

Related Articles

Funding Opportunities: NCI Request for Applications

April 28, 2000

In Brief: Reauthorization May Be Wrapped Up This Week As House, Senate Work Toward Compromise

October 14, 1988

Obesity At Prostate-Cancer Diagnosis Increases Risk

March 30, 2007

BRAF Inhibitor Shrank Tumors In Phase II Genentech Study

November 26, 2010

New Clinical Trials Monitoring Program To Site Visit PIs Every Three Years

July 30, 1982

FDA Committee Approves NDA for Mitxantrone

March 21, 1986